Abstract：
We assessed early antibody responses after two doses of JYNNEOS (IMVANEX) mpox vaccine in the District of Columbia (D.C.) in persons at high risk for mpox without characteristic lesions or rash. Participants with PCR mpox negative specimens (oral swab, blood, and/or rectal swab) on the day of receipt of the first vaccine dose and who provided a baseline (day 0) serum sample and at least one serum sample at ∼28, ∼42-56 days, or 180 days post vaccination were included in this analysis. Orthopoxvirus (OPXV)-specific IgG and IgM ELISAs and neutralizing antibody titers were performed, and longitudinal serologic responses were examined. Based on participants\' IgG and IgM antibody levels at baseline, they were categorized as naïve or non-naïve. Linear mixed effects regression models were conducted to determine if IgG antibody response over time varied by age, sex, HIV status, and route of administration for both naïve and non-naïve participants. Among both naïve and non-naïve participants IgG seropositivity rates increased until day 42-56, with 89.4 % of naïve and 92.1 % of non-naïve participants having detectable IgG antibodies. The proportion of naive participants with detectable IgG antibodies declined by day 180 (67.7 %) but remained high among non-naïve participants (94.4 %). Neutralizing antibody titers displayed a similar pattern, increasing initially post vaccination but declining by day 180 among naïve participants. There were no significant serologic response differences by age, sex, or HIV status. Serologic response did vary by route of vaccine administration, with those receiving a combination of intradermal and subcutaneous doses displaying significantly higher IgG values than those receiving both doses intradermally. These analyses provide initial insights into the immunogenicity of a two-dose JYNNEOS PEP regimen in individuals at high risk of mpox exposure in the United States.
摘要：
我们评估了在哥伦比亚特区（D.C.）服用两剂JYNNEOS（IMVANEX）水痘疫苗后，在没有特征性病变或皮疹的高风险人群中的早期抗体反应。PCR痘病毒阴性标本的参与者（口腔拭子，血,和/或直肠拭子)在收到第一次疫苗剂量的当天，谁提供了基线(第0天)血清样本和至少一个血清样本，时间为28天，42-56天，本分析包括疫苗接种后180天或.进行正痘病毒（OPXV）特异性IgG和IgMELISA和中和抗体滴度，并检查了纵向血清学反应。根据参与者基线时的IgG和IgM抗体水平，他们被归类为天真或非天真。进行线性混合效应回归模型以确定IgG抗体反应随时间的变化是否随年龄而变化。性别,艾滋病毒状况，以及幼稚和非幼稚参与者的给药途径。在初始和非初始参与者中，IgG血清阳性率增加直到第42-56天，89.4％的初始参与者和92.1％的非初始参与者具有可检测的IgG抗体。具有可检测的IgG抗体的幼稚参与者的比例下降了180天（67.7％），但在非幼稚参与者中仍然很高（94.4％）。中和抗体滴度显示出相似的模式，最初在接种疫苗后增加，但在天真的参与者中下降180天。年龄没有显著的血清学反应差异，性别,或艾滋病毒状况。血清学反应确实因疫苗给药途径而异，那些接受皮内和皮下剂量组合的患者显示的IgG值明显高于接受皮内两种剂量的患者。这些分析提供了对美国两剂量JYNNEOSPEP方案的免疫原性的初步见解。
